How Will Technology Evolve Delivery Methods and Formulations - Eric Andrew Appel, PhD

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

International Workshop on Monoclonal Antibodies fo-r HIV, COVID-19, and Oncology 2021 - Implementing Monoclonal Antibodies for Treatment and Prevention in Resource-Limited Settings - How to Make Them Affordable - David Ripin

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

How Will Technology Evolve: Modification of Antibodies - Boris Juelg, MD, PhD

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

How to Determine the Dosing (in Different Populations/Tissues) - Edmund Capparelli, PharmD

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibodies for Treatment in Hematologic Malignancies - Alison Moskowitz, MD

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibodies for Treatment in Autoimmune Diseases - Karmela Kim Chan, MD

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibodies for Prevention of HIV, COVID, and Ebola - Myron Cohen, MD, BS

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibodies for Treatment in COVID-19 - Florence Ader, Prof, MD

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibodies Against COVID-19: Targets, Development and Clinical Applications - Brigette Autran, MD, PhD

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021 - Historical Perspectives from Pasteur to Flexner: The Evolution of Serum to Monoclonal Antibody Therapy- Charles W. Flexner

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021